| Nov 22 |
3 US Growth Companies With High Insider Ownership Seeing Up To 40% Earnings Growth
|
| Nov 21 |
Hims & Hers closes up 10% as Lilly tirzepatide compounding dispute resolution delayed
|
| Nov 21 |
Hims & Hers Expands Nutrition Support to Fuel Customers’ Weight Loss Journeys
|
| Nov 20 |
Guardant Health Stock Sees RS Rating Jump To 83
|
| Nov 20 |
Hims & Hers Health: Far From Dead, Even With Amazon's Threat Ahead
|
| Nov 18 |
Unpacking the Latest Options Trading Trends in Hims & Hers Health
|
| Nov 18 |
Hims & Hers Appoints Tenured Pharmaceutical, Regulatory, and Quality Experts to Key Leadership Positions
|
| Nov 16 |
Hims & Hers: Revolutionizing Telehealth And Captivating Investors - Here's Why You Should Buy
|
| Nov 15 |
Hims & Hers Health: The Amazon Curse Is Being Overstated
|
| Nov 15 |
Netflix, Five Other Gems Soar Into Profit Zones In Hot November Rally
|
